Cyclacel Pharmaceuticals (CYCC)
Cyclacel Pharmaceuticals Revenues: 0.161M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CYCC Revenues Rankings
| Overall | 1st percentile | 4378 of 4425 |
| Sector | 5th percentile | 446 of 470 in Healthcare |
| Industry | 9th percentile | 120 of 132 in Biotechnology |
CYCC Revenues Range, Past 5 Years
| Minimum | 0.013M | Dec 2007 |
| Maximum | 0.271M | Mar 2010 |
| Average | 0.1706M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these CYCC related companies
CYCC News
LONG $PGNX and $MSHL and watching $CYCC if it breaks .57 with power Im long there to .63 then reevaluate
about a day ago by Bud_Stocks
about a day ago by Bud_Stocks
@Urbane_Gorilla http://stks.co/3z5t $CYCC $CELG $BMY $REGN $PFE #ASCO12 checklist
about 4 days ago by biotech
about 4 days ago by biotech
$CYCC share holder meeting today - new presentation : http://stks.co/3xF0
about 5 days ago by biotech
about 5 days ago by biotech
@biotech you have to be short $CYCC cause you been pumpin this thing as a steal since 65 cents-stock is garbage
about 10 days ago by oliveblakcok
about 10 days ago by oliveblakcok
$CYCC .39 dump on 100K CAPITULATION just happend now back to .45 x .46 wow free to run into ASCO12
about 10 days ago by biotech
about 10 days ago by biotech
Cyclacel to Report New Sapacitabine Clinical Data at the American Society of Clinical Oncology Annual Meeting
May 17, 7:00AM GlobeNewswire
May 17, 7:00AM GlobeNewswire
$CYCC biotech-sure your not short this stock? $SNSS gone from 1.40-$2.90 while sh!tlacell gone from 66 pennies to 46 pennies-just saying...
about 13 days ago by oliveblakcok
about 13 days ago by oliveblakcok
$SNSS VS $CYCC marketcap 130M x 30M HMMM ? in same UK trial for AML when will $CYCC hit radars finaly? multibagger imo
about 13 days ago by biotech
about 13 days ago by biotech
$CYCC NEWS out: More than 40% of patients are still alive and longer follow-up is needed to assess overall survival
about 14 days ago by biotech
about 14 days ago by biotech
$CYCC @biotech. Ive been away. Cycc is really cheap now. Loading up on Monday.
about 17 days ago by Novice67
about 17 days ago by Novice67
@oliveblakcok BS i just cant take this anoying $CYCC bashing anymore BTW: $CYCC going up this morning- maybe biorunupstart into #ASCO12 ?
about 18 days ago by biotech
about 18 days ago by biotech
Cyclacel Pharmaceuticals to Announce Release of First Quarter 2012 Financial Results
May 08, 7:00AM GlobeNewswire
May 08, 7:00AM GlobeNewswire
Cyclacel Pharmaceuticals Announces Grant of New U.S. Patent Covering Sapacitabine
Apr 17, 7:04AM Benzinga
Apr 17, 7:04AM Benzinga
Personalized Medicine and Combination Potential of Cyclacel's Sapacitabine Highlighted at AACR
Apr 04, 9:00AM GlobeNewswire
Apr 04, 9:00AM GlobeNewswire
Cyclacel's Novel Polo-Like Kinase 1 (Plk1) Inhibitors Highlighted at AACR
Apr 02, 2:00PM GlobeNewswire
Apr 02, 2:00PM GlobeNewswire
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Mar 29, 4:01PM GlobeNewswire
Mar 29, 4:01PM GlobeNewswire
Cyclacel Provides Corporate Update at OneMedForum Conference; Re-Analysis "Insufficient"
Jan 11, 12:27PM Benzinga
Jan 11, 12:27PM Benzinga
Cyclacel says study highlights safety, efficacy of sapacitabine with decitabine
Dec 12, 1:07PM theflyonthewall.com
Dec 12, 1:07PM theflyonthewall.com
Cyclacel to Webcast Analyst & Institutional Investor Meeting Wednesday, December 7, 2011
Dec 01, 7:00AM GlobeNewswire
Dec 01, 7:00AM GlobeNewswire
Cyclacel to Announce Third Quarter 2011 Financial Results and Upcoming Corporate Events
Nov 07, 7:00AM GlobeNewswire
Nov 07, 7:00AM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CYCC | 0.5124 | -0.02 | -3.32% | 27.79M |
| CYBI | 1.761 | -0.03 | -1.62% | 30.15M |
| CYBE | 8.34 | +0.00 | +0.00% | 57.80M |
| CYB | 25.22 | +0.00 | +0.00% | |
| CYAN | 7.60 | -0.15 | -1.94% | 41.12M |
| CY | 13.25 | +0.11 | +0.84% | 2.052B |
| CSGS | 16.38 | +0.09 | +0.55% | 565.27M |
| CSGP | 72.67 | -0.29 | -0.40% | 1.849B |
| CSFS | 5.50 | +0.00 | +0.00% | 95.86M |
| CSFL | 7.31 | -0.21 | -2.79% | 219.81M |